Trop-2 mRNA expression and association with clinical outcomes with sacituzumab govitecan (SG) in patients with HR+/HER2– metastatic breast cancer (mBC): Biomarker results from the phase 3 TROPiCS-02 study.

Authors

Aditya Bardia

Medical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA

Aditya Bardia , Hope S. Rugo , Javier Cortés , Sara M. Tolaney , Peter Schmid , Monica Motwani , Oh Kyu Yoon , Jillian Boice , Luting Zhuo , Frederik Marmé

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Endocrine therapy resistance (ETR) in hormone receptor-positive, HER2-negative metastatic breast cancer (HR+, HER2– mBC): Prevalence, biomarker characteristics, and outcomes.

First Author: Rinath Jeselsohn

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low, hormone receptor-positive (HR+) unresectable and/or metastatic breast cancer (mBC): Exploratory biomarker analysis of DESTINY-Breast04.

First Author: Shanu Modi

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Ribociclib (RIB) vs. palbociclib (PAL) in patients (pts) with hormone receptor-positive/HER2-negative/HER2-enriched (HR+/HER2-/HER2-E) advanced breast cancer (ABC): A head-to-head phase III study—HARMONIA SOLTI-2101/AFT-58.

First Author: Tomás Pascual

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Neratinib plus fulvestrant plus trastuzumab (N+F+T) for hormone receptor-positive (HR+), HER2-negative, HER2-mutant metastatic breast cancer (MBC): Outcomes and biomarker analysis from the SUMMIT trial.

First Author: Komal L. Jhaveri